RxDoctor Payments Data

Yerusalem Lanier

Podiatrist · Worcester, MANPI 1760836290

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (59.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 61.2% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $2,263, 2.0 times the $1,114 reported in 2019.

$5,810in general payments, 2019–2025

Across 181 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$4K
  • Osteomed LLC$1K
  • Organogenesis Inc.$397
  • Medical Device Business Services, Inc.$255
  • GRT US Holding, Inc.$66
  • Johnson & Johnson$59
  • plus $392 from 19 others

What the payments were for

  • Travel & lodging$2,32940%
  • Food & beverage$3,45559%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,810 in reported general payments places this provider in the 85th percentile of 179 podiatrist providers in Massachusetts.

See all podiatrist providers in Massachusetts

Medicare billing

Part B allowed, 2024
$383,367
Medicare patients
447
Services billed
2,229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox24$958
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$373
Cephalexin32$318
Ketoconazole19$212
Clindamycin Hcl21$199
Ciprofloxacin Hcl18$171
Terbinafine Hcl17$157
Methylprednisolone20$133
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$133
Meloxicam35$76
Tramadol Hcl11$20

Paid to pharmacies, not to this prescriber.

Other podiatrist in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →